Related Experiment Video
Updated: Jul 8, 2026
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
Selective dopamine D3 receptor antagonists: a review 2001-2005
Fabrizio Micheli1, Christian Heidbreder
1Department of Medicinal Chemistry, Glaxo SmithKline S.p.A., Via A. Fleming 4, 37135 Verona, Italy.
Recent Patents on CNS Drug Discovery
|January 29, 2008
Summary
Selective dopamine D(3) receptor antagonists show promise for treating addiction, cognitive deficits, and schizophrenia. Preclinical studies reveal their efficacy in reducing drug-seeking behavior and improving cognitive function.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Dopamine D(3) receptors are implicated in drug-seeking behavior, impulse control disorders, and schizophrenia.
- Testing the role of dopamine D(3) receptors was challenging due to a lack of selective compounds.
Purpose of the Study:
- To review current research and future developments of selective dopamine D(3) receptor antagonists.
- To outline patents and publications in this field from 2001-2005.
Main Methods:
- Review of approximately 40 patents and 100 publications.
- Analysis of preclinical animal models investigating dopamine D(3) receptor antagonism.
Main Results:
- Selective dopamine D(3) receptor antagonists reduce the reinforcing effects of drugs of abuse.
- Antagonism at dopamine D(3) receptors reverses cognitive deficits in animal models.
- Demonstrated efficacy in animal models relevant to schizophrenia.
Conclusions:
- Selective dopamine D(3) receptor antagonists show significant therapeutic potential for neuropsychiatric diseases.
- Further development of these compounds may lead to novel pharmacotherapies.
Related Concept Videos
01:21Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...